Clenbuterol Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Clenbuterol dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Clenbuterol.
Dosing Protocols
Clenbuterol has no beginner protocol recommended by BodyHackGuide for fat loss or body recomposition purposes. We do not endorse beginner use of clenbuterol for aesthetic or athletic goals at any dose. For the legitimate clinical indication of asthma bronchodilator therapy in jurisdictions where clenbuterol is an approved medication, the established adult dosing is 20 mcg orally twice daily, titratable to 40 mcg twice daily if needed, with ongoing medical supervision by a pulmonologist or primary care physician. In the United States, Canada, UK, and Australia, clenbuterol is not approved for human medical use and inhaled beta-2 agonists (albuterol, salmeterol, formoterol) are the standard bronchodilators for asthma management. If you are considering clenbuterol for fat loss, the BodyHackGuide recommendation is: do not. The evidence base supporting meaningful fat loss from clenbuterol in healthy humans at any tolerable dose is thin, and the cardiotoxicity, rhabdomyolysis, hypokalemia, and case-report harms are substantial. Safer approaches: a targeted 300-500 kcal/day caloric deficit combined with resistance training, adequate protein (1.6-2.2 g/kg), moderate caffeine and green tea catechins, and patience (0.5-1% body weight loss per week is sustainable). For medical obesity management, GLP-1 receptor agonists prescribed by a physician offer superior evidence and safety.
Clenbuterol has no intermediate protocol recommended by BodyHackGuide for fat loss or body recomposition purposes. Users who have attempted clenbuterol previously and are considering repeat use are strongly encouraged to reconsider. The specific risks that accumulate with repeat or escalating clenbuterol exposure — progressive beta-2 receptor desensitization requiring dose escalation, cumulative cardiac remodeling risk (documented in animal models and inferred in humans), repeated hypokalemia episodes, and rhabdomyolysis risk — make repeated cycling a higher-risk strategy than a single exposure. For athletes subject to anti-doping testing (WADA, USADA, NCAA, US military, high school sports), clenbuterol is banned and has a long detection window (up to 8-21 days in urine testing depending on dose and sensitivity); a detected clenbuterol metabolite without documented meat contamination evidence results in standard 4-year bans for most first offenses. For physique contest preparation within natural federations (INBF, WNBF, OCB, Drug Free Athletics Coalition), clenbuterol disqualifies an athlete. For contest preparation within tested professional bodybuilding, same outcome. For untested professional bodybuilding (IFBB Pro, NPC), clenbuterol is legal within the sport's culture but the health risk profile remains unchanged. If you are using clenbuterol repeatedly despite these considerations, the best harm-reduction approach includes: pre-cycle cardiac screening (12-lead ECG, echocardiogram, baseline troponin, electrolyte panel), dosing limited to 40-80 mcg/day rather than escalating to 120+, strict 2-week-on / 4-week-off cycling (longer off periods than the common 2-on/2-off protocol to allow fuller receptor resensitization), concurrent potassium (200-400 mg/day), magnesium (400-600 mg/day), and taurine (3-5 g/day) supplementation, avoidance of concurrent thyroid hormone, yohimbine, ephedrine, and other sympathomimetic stimulants, and immediate cessation with cardiology evaluation if chest pain, palpitations beyond baseline tachycardia, syncope, or exercise-induced symptoms develop.
Clenbuterol has no advanced protocol recommended by BodyHackGuide for fat loss or body recomposition purposes. The high-dose bodybuilding approach (120-200+ mcg/day, escalating, long cycles) is where the published serious adverse event case reports — takotsubo cardiomyopathy, ventricular tachycardia, rhabdomyolysis with acute kidney injury, myocardial infarction — concentrate. BodyHackGuide explicitly does not publish a recipe for high-dose clenbuterol use because there is no dose range at which the cardiovascular risk profile becomes acceptable for body composition goals in healthy individuals. For advanced physique athletes, contest preparation approaches built on disciplined nutrition, resistance training, cardio programming, and legal supplements (creatine, beta-alanine, caffeine, citrulline) reliably produce contest-ready physiques without the cardiotoxicity risk. Professional bodybuilders who choose to use clenbuterol do so within a culture that accepts substantial long-term health risk; this is an individual choice that is outside BodyHackGuide's scope to protocol-ize. If you are a professional physique competitor intending to use clenbuterol, work with a physician experienced with physique athlete medical management for pre-cycle cardiac workup, intra-cycle monitoring, and post-cycle recovery — not with an online protocol guide. The medical literature contains sufficient high-dose clenbuterol toxicity case reports (hundreds in the English-language literature) to consider the advanced high-dose approach a meaningful cardiac risk factor regardless of concurrent supplementation or monitoring.
Commonly Stacked With
Clenbuterol is commonly combined with other compounds in bodybuilding and physique contest preparation contexts. Each of these combinations carries specific risks that compound clenbuterol's own toxicity profile. BodyHackGuide does not endorse any of these stacks for fat loss purposes and covers them here primarily to warn against combinations that produce serious harm. Clenbuterol + T3 (liothyronine) / T4 (levothyroxine) — The "ECA-for-pros" / "clen-T3 stack": Combining clenbuterol with exogenous thyroid hormone is among the most cardiotoxic fat-loss strategies in common use. Both compounds increase heart rate, cardiac output, core temperature, and metabolic rate through independent mechanisms (beta-2 adrenergic agonism versus thyroid receptor activation). Combined, the cardiovascular stress is cumulative, with resting heart rates commonly exceeding 110-120 bpm at rest and peak tachycardia approaching dangerous territory during exercise or stress. Hypokalemia from clenbuterol and mild muscle catabolism from supraphysiologic T3 compound each other. Case reports of clen-T3 combination producing tachyarrhythmias, rhabdomyolysis, and hospitalizations are published. BodyHackGuide recommends against this combination. Clenbuterol + yohimbine — Yohimbine is an alpha-2 adrenergic antagonist that blocks negative feedback on sympathetic neurons, raising norepinephrine release and producing thermogenic and lipolytic effects. Combined with clenbuterol, the sympathetic overstimulation risk is substantial: anxiety, panic attacks, hypertensive events, and tachyarrhythmias. Yohimbine alone has caused emergency presentations; combined with clenbuterol the risk is amplified. Not recommended. Clenbuterol + ECA stack (ephedrine-caffeine-aspirin) — The ECA stack is an older thermogenic combination that operates through alpha-1 / beta adrenergic agonism (ephedrine) plus adenosine antagonism and PDE inhibition (caffeine). Adding clenbuterol provides further beta-2 stimulation and sustained receptor activation. The combined cardiovascular and CNS stimulant load is extreme: severe tachycardia, hypertension, anxiety, insomnia, possible cardiac events. Not recommended. Clenbuterol + anabolic androgenic steroids (testosterone, trenbolone, etc.) — AAS are commonly stacked with clenbuterol in physique contest preparation to preserve or build lean mass while clenbuterol handles fat loss and provides additional muscle-sparing effects. The AAS-specific risks (hepatotoxicity with 17-alpha-alkylated orals, lipid changes, cardiovascular remodeling, HPG suppression) are additive with clenbuterol's cardiovascular risks. BodyHackGuide does not cover AAS protocols. Clenbuterol + GH/IGF-1 or GH fragments (AOD-9604, HGH Fragment 176-191) — Growth hormone and GH-related peptides are sometimes stacked with clenbuterol for fat loss with lean tissue preservation. The combinations are theoretically synergistic (beta-2-mediated lipolysis plus GH-mediated lipolysis and IGF-1-mediated anabolism) but the cardiovascular risk of clenbuterol remains the dominant limiting factor. GH-related compounds add their own risk profile (insulin resistance, fluid retention, joint pain). Clenbuterol + potassium / taurine / magnesium supplementation — This is a commonly recommended mitigation strategy given clenbuterol's hypokalemia and muscle cramp effects. Typical protocols include potassium chloride 200-400 mg/day, taurine 3-5 g/day, and magnesium (glycinate or citrate forms) 400-600 mg/day. These supplements can partially offset the electrolyte derangements and muscle cramping but do not meaningfully reduce cardiovascular risk and should not be interpreted as making clenbuterol safe. Clenbuterol + beta-blockers — Sometimes recommended by misinformed users to "manage" the tachycardia from clenbuterol. This combination is pharmacologically contradictory (the beta-blocker antagonizes clenbuterol's effects) and can produce unpredictable cardiovascular responses including bronchospasm in susceptible individuals and loss of the thermogenic/lean-sparing effect users are pursuing. The rational answer to "clenbuterol is giving me too much tachycardia" is discontinuation, not adding a beta-blocker. Clenbuterol + caffeine at moderate doses — Even moderate caffeine (200-400 mg/day) combined with clenbuterol produces meaningful additive cardiovascular stress and anxiety. Users commonly report needing to cut or eliminate coffee during clenbuterol cycles due to compounded stimulation. Alternatives BodyHackGuide recommends for the same goals: For fat loss, targeted caloric restriction (300-500 kcal deficit), resistance training to preserve lean mass, moderate protein intake (1.6-2.2 g/kg body weight), and moderate caffeine and green tea catechins are the evidence-based foundation. For refractory weight loss or obesity with metabolic comorbidities, GLP-1 receptor agonists (semaglutide, tirzepatide) prescribed by a physician have substantial RCT evidence for meaningful fat loss with manageable side effects. For physique athletes near contest, the combination of careful caloric restriction, strategic carbohydrate and sodium manipulation, and (if indicated and supervised) short-term metformin or low-dose sympathomimetics has an evidence base without the cardiotoxicity profile of clenbuterol.
Related Compounds — Deeper Research Paths — Clenbuterol is a beta-2 agonist lipolytic; peptide-side alternatives with better safety profiles: AOD-9604 (HGH fragment, lipolysis without cardiac risk), Tesamorelin (visceral fat), HGH Fragment 176-191, Tirzepatide, Retatrutide, Cagrilintide, Semaglutide, Tesofensine (triple monoamine reuptake). Stimulant alternatives: DMHA, Theacrine. Thyroid-axis adjuncts: T3/T4 blend. Metabolic support: L-Carnitine, CoQ10, Berberine.
Side Effects & Safety
Contraindications
Absolute contraindications to clenbuterol use include: pre-existing cardiovascular disease of any kind (coronary artery disease, prior myocardial infarction, ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, heart failure of any etiology, atrial or ventricular arrhythmias, long QT syndrome, prior cardiac arrest); uncontrolled hypertension (>140/90 sustained); pheochromocytoma or suspected pheochromocytoma; hyperthyroidism (untreated or overtreated); pregnancy and breastfeeding; known hypersensitivity to clenbuterol or other beta-2 agonists; active rhabdomyolysis or recent (within 30 days) rhabdomyolysis history; baseline hypokalemia (K+ <3.5 mEq/L) or conditions predisposing to hypokalemia; seizure disorder; pheochromocytoma. Relative contraindications (use only with specialist supervision and specific indication): controlled hypertension with target end-organ damage; type 1 or type 2 diabetes (clenbuterol produces hyperglycemia and can destabilize glucose control); subclinical hyperthyroidism; elderly (>65); adolescents and young adults under age 18; renal or hepatic insufficiency (altered clearance); obstructive sleep apnea; migraine with aura; psychiatric conditions including anxiety disorders, panic disorder, bipolar disorder, and psychotic disorders (clenbuterol can worsen or precipitate symptoms); concurrent CNS stimulant medication use (amphetamines, methylphenidate, modafinil — though modafinil interaction is mild compared to amphetamine-class); concurrent thyroid hormone therapy beyond replacement doses. Specific situations requiring additional caution: athletes subject to anti-doping testing (clenbuterol is banned by WADA with 8-21 day detection windows — high risk of sanctions); athletes in weight-class sports (combat sports, powerlifting, bodybuilding at tested federations); military service members subject to drug testing; law enforcement and public safety officers subject to drug testing. Pre-use medical evaluation should include: detailed cardiovascular history and family history (sudden cardiac death, cardiomyopathy, arrhythmia); resting 12-lead ECG; baseline electrolyte panel (sodium, potassium, magnesium, chloride, bicarbonate); renal function (creatinine, BUN); liver function (AST, ALT, alkaline phosphatase, bilirubin); thyroid function (TSH, free T4); fasting glucose and HbA1c; blood pressure verification over multiple readings; cardiac risk factor assessment (lipid panel, family history). Medical supervision during use (if proceeding despite recommendations against use) should include: weekly or bi-weekly blood pressure and resting heart rate checks; electrolyte monitoring at 2-4 week intervals; prompt discontinuation and cardiology evaluation for chest pain, severe palpitations, syncope, exertional symptoms, or any new cardiac symptoms. Emergency evaluation is indicated for acute chest pain, sustained tachycardia >150 bpm, severe hypertension, syncope, seizure, severe muscle weakness, dark urine (suggestive of rhabdomyolysis), or symptoms suggesting acute myocardial infarction.
Additional Notes
Clenbuterol is available in multiple pharmaceutical and grey-market formulations with widely varying concentrations, making accurate dosing an ongoing safety concern. The standard pharmaceutical formulations (Spiropent, Broncoterol, Dilaterol, Novegam) are typically 20-microgram oral tablets or 0.01-0.02 mg/mL oral syrup for asthma dosing. Therapeutic adult dosing is 20 mcg twice daily, titratable to 40 mcg twice daily. Grey-market "research chemical" liquid clenbuterol is commonly sold at 200 mcg/mL concentrations but product concentration varies significantly between vendors and batches; independent testing has documented products labeled 200 mcg/mL that actually contain 100-300 mcg/mL. Tablet products from foreign pharmaceutical sources are generally more reliable for concentration accuracy than research-chemical liquids but carry customs/legal risk. For users who proceed with clenbuterol despite the cardiotoxicity profile, dosing considerations include: (1) start low — typical initial doses are 20-40 mcg/day to assess tolerance before escalation; (2) titrate slowly, ideally no more than 20 mcg/day increments every 2-3 days; (3) do not exceed 120 mcg/day for sustained periods — the dose-response for adverse events steepens substantially above this range with marginal additional fat-loss benefit; (4) morning-only dosing is preferred to preserve sleep — evening doses produce profound insomnia due to the 26-36 hour half-life; (5) due to long half-life, clenbuterol does not require multiple daily dosing — single daily morning dose is sufficient; (6) skip-dose cycling (2 weeks on / 4 weeks off) is marginally better than continuous dosing for receptor resensitization; (7) electrolyte monitoring (potassium, magnesium) at 2-week intervals during active use if feasible; (8) heart rate monitoring — sustained resting heart rate >100 bpm or any chest pain or palpitations warrants immediate discontinuation and cardiology evaluation. Weight-based dosing has been suggested in some bodybuilding guides but is not clinically validated — adult humans receive similar clenbuterol tissue exposure across normal body weights due to the drug's modest volume of distribution and primarily hepatic clearance. Pediatric dosing is not addressed here because clenbuterol is not appropriate for pediatric use outside of narrow respiratory indications under specialist supervision. Pregnancy — avoid. Breastfeeding — avoid.
Frequently Asked Questions
What is the recommended Clenbuterol dosage?
Dosage for Clenbuterol varies by protocol. Consult a qualified healthcare provider.
How often should I take Clenbuterol?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Clenbuterol need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Clenbuterol side effects?
Clenbuterol has a substantial side effect profile that can be subdivided by dose level and chronicity. At therapeutic bronchodilator doses (20-40 mcg BID), side effects are manageable but notable: tremor (especially hand tremor, reported by 50-70% of users early in treatment, typically attenuating over 1-2 weeks), palpitations and mild tachycardia (15-25% of users), headache, muscle cramps, insomnia particularly with evening dosing, anxiety, and GI upset. Tolerance to tremor and cardiovascular effects develops with sustained dosing due to beta-2 receptor desensitization. These therapeutic-dose effects are generally tolerable in an asthma treatment context where the benefit-risk balance is established. At bodybuilding doses (commonly 80-160 mcg/day, sometimes escalating to 200-300+ mcg/day), the side effect profile becomes clinically significant and potentially dangerous: Cardiovascular effects dominate the risk profile. Tachycardia is nearly universal, with resting heart rates commonly rising to 90-120 beats per minute (bpm) or higher. Palpitations, chest discomfort, and atypical chest pain are frequent. Published case reports document ventricular tachycardia, atrial fibrillation, supraventricular tachycardia, and sustained arrhythmias requiring emergency cardioversion. Blood pressure typically rises 10-20 mmHg systolic in early treatment. Myocardial infarction in structurally normal coronaries has been reported in young otherwise healthy users — Kim et al. 2019documented cases of troponin elevation, wall motion abnormalities, and takotsubo-like stress cardiomyopathy in clenbuterol users. Chronic use in animal models produces cardiomyocyte apoptosis, cardiac hypertrophy, and fibrosis (Burniston et al. 2006; Yen et al. 2013) — whether humans develop comparable subclinical cardiac changes with chronic use is not fully characterized but is biologically plausible. Electrolyte derangements: Hypokalemia is the most serious electrolyte effect, with serum potassium commonly falling 0.3-0.8 mEq/L during active use and occasionally to dangerous levels (<2.5 mEq/L) in overdose or heavy misuse. Hypokalemia is the proximate cause of many of the serious arrhythmias reported in clenbuterol users. Hypomagnesemia and hypophosphatemia can also occur. Hyperglycemia: Clenbuterol stimulates hepatic glycogenolysis and gluconeogenesis, producing acute blood glucose elevations of 20-40 mg/dL and mild insulin resistance. Typically transient and not problematic in non-diabetic users but worth noting. Neuromuscular effects: Pronounced hand tremor, sometimes generalized tremor, muscle cramps (particularly in calves and feet — taurine and magnesium supplementation are commonly recommended to reduce cramping), and rarely rhabdomyolysis. Rhabdomyolysis has been reported in multiple case reports including Ramos et al. 2022 and has resulted in acute kidney injury requiring dialysis in severe cases. The proposed mechanism involves direct beta-2 stimulation of skeletal muscle combined with hypokalemia-induced muscle membrane instability. CNS effects: Insomnia is nearly universal with clenbuterol use, often severe. Anxiety, restlessness, jitteriness, and subjective "wired" feelings are common. Some users experience panic attacks. Headache is common. Metabolic and thermogenic effects: Increased sweating, subjective hot flushes, increased core body temperature (0.5-1°C). These are the "felt effects" that users sometimes interpret as evidence of ongoing thermogenesis — and are genuinely occurring — but also constitute physiologic stress. GI effects: Nausea, diarrhea, loss of appetite, dry mouth. Endocrine effects: Suppression of pituitary prolactin secretion, mild changes in thyroid axis, no significant effect on gonadal axis in most users. Rare serious adverse effects: Acute myocardial infarction, stroke, sudden cardiac death (very rare but documented), severe rhabdomyolysis with acute kidney injury, seizures (rare, likely in context of hypokalemia or overdose). Withdrawal: Clenbuterol does not produce a physical dependence syndrome comparable to opioids, but cessation after prolonged use can produce rebound lethargy, fatigue, mild depression, and some subjective "crash" as the sympathomimetic stimulation and elevated metabolic rate normalize. These effects are typically mild and resolve within 1-2 weeks. Tolerance: Beta-2 receptor desensitization develops within 2-3 weeks of continuous use, attenuating both the thermogenic effect and some side effects. The common response is dose escalation, which compounds cardiovascular risk. Cycling (2 weeks on / 2 weeks off) is a user strategy that does not actually restore receptor function within 2 weeks — desensitization may take 4-6 weeks to reverse — but is widely practiced. Drug interactions: Beta-blockers (propranolol, metoprolol, etc.) — pharmacologic antagonists; concurrent use blocks clenbuterol's effects and can produce unpredictable cardiovascular responses. Stimulants (caffeine at high doses, ephedrine, amphetamines, cocaine) — additive cardiovascular stress; particularly dangerous combination. Thyroid hormone (T3, T4) — often combined in bodybuilding contexts but additive cardiovascular risk and the combined effects on heart rate, blood pressure, and metabolic rate substantially compound risk. Diuretics — additive hypokalemia risk. Digoxin — hypokalemia from clenbuterol increases digoxin toxicity risk. MAO inhibitors — may enhance catecholamine effects. Contraindications include: known cardiovascular disease (coronary artery disease, hypertension, arrhythmias, cardiomyopathy, heart failure); hyperthyroidism; pheochromocytoma; uncontrolled diabetes; pregnancy and breastfeeding; pediatric use (limited data, higher risk); known hypersensitivity. Special populations: Pregnancy — clenbuterol is sometimes used off-label for tocolysis (inhibition of preterm labor) in veterinary obstetrics but is not recommended for human pregnancy outside of narrow research contexts. Breastfeeding — distributes into milk; avoid. Overdose presentation and management: Acute clenbuterol overdose presents with severe tachycardia (HR > 150 bpm), hypertension or hypotension, hypokalemia, hyperglycemia, tremor, agitation, possible seizure, and rhabdomyolysis. Management involves supportive care, cardiac monitoring, potassium replacement, magnesium replacement, beta-blockade for severe tachycardia/hypertension (non-selective beta-blockers like propranolol are preferred), IV fluids, and ICU admission for severe cases. The long half-life means clinical effects persist 24-72 hours after presentation. Overall, clenbuterol's side effect profile at bodybuilding doses is substantial enough that BodyHackGuide does not consider the risk-benefit favorable for fat loss or body recomposition in healthy individuals regardless of cycle structure or dose titration approach.
Where can I buy Clenbuterol?
Visit our vendor directory to find trusted sources for Clenbuterol.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
